Technology News and Research

RSS

Yale chemists synthesize complex anticancer molecules from marine invertebrates

Nearly 30 years ago, scientists discovered a unique class of anticancer molecules in a family of bryozoans, a phylum of marine invertebrates found in tropical waters.

22 Feb 2024

Innovative MicroGlucagon solution aims to transform insulin therapy for type 1 diabetics

Researchers in Trondheim are developing a new medicine for diabetics who have to have daily injections of insulin. The key is a hormone that causes the smallest blood vessels to relax on the inside.

22 Feb 2024

MD Anderson acquires cell therapy safety technology from Bellicum Pharmaceuticals

The University of Texas MD Anderson Cancer Center today announced it has acquired certain assets from Bellicum Pharmaceuticals, Inc. related to the CaspaCIDe switch platform and the GoCAR platform.

22 Feb 2024

Ginseng enhances muscle recovery and reduces fatigue in athletes

Ginseng is one of the most popular food supplements in the world. It is made out of various plants and herbs and is thought to provide many benefits, with numerous studies pointing at possible anti-inflammatory and antioxidant benefits as well as anti-cancer effects.

22 Feb 2024

Delta opioid receptor agonist reduces anxiety-like behavior in mice

Anxiety-related disorders can have a profound impact on the mental health and quality of life of affected individuals.

22 Feb 2024

LabVantage Solutions Introduces Digital Native Ecosystem for R&D Success

With solutions to decrease redundant experiments, improve design of experiments, derive greater insights from data, and automate laboratory workflows, LabVantage Solutions equips R&D labs for success in innovation. Introducing a digital native ecosystem for R&D, LabVantage addresses researchers’ needs in three broad categories of semantic search, analytics, and automation.

From LabVantage Solutions 22 Feb 2024

Aptamer and Neuro-Bio enter the second phase of Alzheimer’s test development

Aptamer Group plc, the developer of novel Optimer binders to enable innovation in the life sciences industry, announces the second phase of its on-going partnership with Neuro-Bio, an Oxfordshire-based biotechnology company with a therapeutic focus on neurodegenerative disease, to develop Optimer binders for a lateral flow test for the early diagnosis of Alzheimer’s disease

From Aptamer Group 22 Feb 2024

Youth fitness linked to lower atherosclerosis risk in middle-aged men

Men who were physically fit when they were young had a lower risk of atherosclerosis almost 40 years later, according to a study led by researchers at Linköping University, Sweden.

22 Feb 2024

SCIEX’s Jose Castro-Perez Reveals How They're Setting New Standards in Mass Spectrometry

SCIEX’s Reveals How They're Setting New Standards in Mass Spectrometry at SLAS 2024.

From Society for Laboratory Automation and Screening (SLAS) 22 Feb 2024

Simple blood test to detect Alzheimer's disease may replace more invasive diagnostic methods

A simple blood test to diagnose Alzheimer's disease soon may replace more invasive and expensive screening methods such as spinal taps and brain scans.

22 Feb 2024

Red light exposure mitigates blood glucose spikes after meals

Shining a specific frequency of red light on a person's back for 15 minutes can reduce blood sugar levels, according to a new study from City, University of London and UCL.

22 Feb 2024

Selkirk Pharma announces new APS qualified facility with advanced fill/finish capacity in Spokane, WA

Selkirk Pharma, Inc., a privately held U.S. pharmaceutical manufacturer specializing in the fill and finish of injectable drugs, including vaccines and biological therapeutics, today announced the Aseptic Process Simulation (APS) qualification of its sterile manufacturing facility and newly available fill/finish capacity.

From Selkirk Pharma 22 Feb 2024

Novel treatment for polycythemia vera shows promise in clinical trial

A novel treatment for polycythemia vera, a potentially fatal blood cancer, demonstrated the ability to control overproduction of red blood cells, the hallmark of this malignancy and many of its debilitating symptoms in a multi-center clinical trial led by the Icahn School of Medicine at Mount Sinai.

21 Feb 2024